Cassandra Munoz-Parsons
Family Medicine · Falls City, NENPI 1366999344
Payments from drug & device makers
Across 175 payments — averaging $15.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$845
- Otsuka America Pharmaceutical, Inc.$384
- Lilly USA, LLC$246
- Johnson & Johnson$152
- Novo Nordisk$107
- Teva Pharmaceuticals USA, Inc.$101
- plus $903 from 21 others
What the payments were for
- Food & beverage$2,738100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 59 | $845 |
| Otsuka America Pharmaceutical, Inc. | 22 | $384 |
| Lilly USA, LLC | 13 | $246 |
| Johnson & Johnson(2 entities) | 9 | $152 |
| Novo Nordisk | 7 | $107 |
| Teva Pharmaceuticals USA, Inc. | 7 | $101 |
| Viiv Healthcare Company | 6 | $97 |
| Neurocrine Biosciences, Inc. | 6 | $90 |
| Boehringer Ingelheim | 6 | $80 |
| Pfizer | 5 | $72 |
| Vanda Pharmaceuticals Inc. | 4 | $68 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $64 |
| Merck | 3 | $56 |
| Abbott | 3 | $52 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $45 |
| AstraZeneca | 3 | $44 |
| Alkermes, Inc. | 2 | $38 |
| Gilead | 2 | $35 |
| Genentech USA, Inc. | 2 | $27 |
| E.r. Squibb & Sons, L.L.C. | 2 | $26 |
| Clarus Therapeutics Inc. | 1 | $18 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $18 |
| Sanofi-aventis U.S. LLC | 1 | $18 |
| Medtronic | 1 | $17 |
| Ironwood Pharmaceuticals, Inc | 1 | $13 |
| Axsome Therapeutics, Inc. | 1 | $13 |
| Astellas Pharma US Inc | 1 | $13 |
How this compares
$2,738 in reported general payments places this provider in the 80th percentile of 981 family medicine providers in Nebraska.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 13 | $448 |
| Mirtazapine | 38 | $369 |
| Risperidone | 21 | $292 |
| Duloxetine Hcl | 12 | $233 |
| Quetiapine Fumarate | 19 | $204 |
| Prazosin Hcl | 12 | $182 |
| Gabapentin | 11 | $120 |
| Lamotrigine | 21 | $118 |
| Aripiprazole | 19 | $103 |
| Olanzapine | 11 | $103 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 16 | $102 |
| Alprazolam | 13 | $97 |
| Escitalopram Oxalate | 21 | $88 |
| Trazodone Hcl | 12 | $74 |
| Topiramate | 11 | $55 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCOlanzapine | $246 | $10311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 981 family medicine providers in Nebraska.
Other family medicine in Falls City
- Brandon EssinkCreighton$92.8M
- Adam BroszGrand Island$60M
- David EnszSouth Sioux City$33.3M
- Allen HuntLincoln$17.2M
- Thomas WolfFremont$8.2M
- William FitzgibbonsElkhorn$7M
- Kenneth BladOmaha$1.6M
- Lorrie McGillPapillion$1.5M
- Ralph HaukeOmaha$657K
- Darin GregoryOmaha$423K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.